Arexvy has been approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older. This is the first RSV vaccine to be approved in the United States.

RSV is a highly contagious virus that causes infections of the lungs and breathing passages in individuals of all age groups. RSV circulation is seasonal, typically starting during the fall and peaking in the winter. Older adults with underlying health conditions are at high risk for severe disease caused by RSV.

Specifically in older adults, RSV is a common cause of lower respiratory tract disease (LRTD), which affects the lungs and can cause life-threatening pneumonia and bronchiolitis. According to the U.S. Centers for Disease Control and Prevention, each year in the U.S., RSV leads to approximately 60,000-120,000 hospitalizations and 6,000-10,000 deaths among adults 65 years of age and older.

Click here for more information.